Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...

Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease) - Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...

Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...

Vaccinex Announces the Publication of Data Demonstrating Preclinical Efficacy in an Animal Model of Huntington Disease ROCHESTER, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage immunotherapy company engaged in the discovery and development of therapeutic monoclonal antibodies, today announced...